FIND DRUGS:

BRAND NAME GENERIC NAME INDICATION MANUFACTURERS COMPARE DRUGS

FEATURES


Viewpoints

AACR Cancer Progress Report Urges Increased Congressional Funding for NCI and NIH Research Budgets

AACR Cancer Progress Report Urges Increased Congressional Funding for NCI and NIH Research Budgets

Newly released 2014 Cancer Progress Report from the American Association for Cancer Research highlights the need for increased federal funding of cancer research.

Genomic Research Indicates the Need for Cancer Reclassification

Genomic Research Indicates the Need for Cancer Reclassification

1 in 10 patients with cancer would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria.

Feature Articles

PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy

PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy

Immunotherapeutic approaches to treating cancer have been evaluated during the last few decades with limited success.

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Although ADT remains an important treatment, its use as primary therapy in low-risk prostate cancer seems increasingly ill advised.

Biomarkers of HIV-associated Cancer

Biomarkers of HIV-associated Cancer

Biomarkers can provide great opportunities in the management of the most common HIV-associated malignancies, namely, Kaposi sarcoma, non-Hodgkin's lymphoma, and invasive cervical cancer.

Slideshows

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed follicular non-Hodgkin lymphoma (FL).

Table of Contents

Slide 3: Indication, Dosage, ...

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide ...

From the Advisory Board

Lost in Translation: Communicating with Newly Diagnosed Cancer Patients

Lost in Translation: Communicating with Newly Diagnosed Cancer Patients

Dr. Dizon and patient advocate Katherine O'Brien discuss the difficulty of communicating cancer and give advice on common miscommunications.

CME

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.

Sign Up for Free e-newsletters

CTA Community Poll

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs